These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27707539)

  • 21. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
    Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
    J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
    Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
    J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
    Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene.
    Venturini A; Borrelli A; Musante I; Scudieri P; Capurro V; Renda M; Pedemonte N; Galietta LJV
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
    Van Goor F; Yu H; Burton B; Hoffman BJ
    J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough.
    Lee RE; Lewis CA; He L; Bulik-Sullivan EC; Gallant SC; Mascenik TM; Dang H; Cholon DM; Gentzsch M; Morton LC; Minges JT; Theile JW; Castle NA; Knowles MR; Kimple AJ; Randell SH
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35900863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
    Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
    Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
    Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
    J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
    Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
    Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
    Ramsey BW; Davies J; McElvaney NG; Tullis E; Bell SC; Dřevínek P; Griese M; McKone EF; Wainwright CE; Konstan MW; Moss R; Ratjen F; Sermet-Gaudelus I; Rowe SM; Dong Q; Rodriguez S; Yen K; Ordoñez C; Elborn JS;
    N Engl J Med; 2011 Nov; 365(18):1663-72. PubMed ID: 22047557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
    van de Peppel IP; Doktorova M; Berkers G; de Jonge HR; Houwen RHJ; Verkade HJ; Jonker JW; Bodewes FAJA
    J Cyst Fibros; 2019 Mar; 18(2):286-293. PubMed ID: 30279125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.
    Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA
    Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
    Abou Alaiwa MH; Launspach JL; Grogan B; Carter S; Zabner J; Stoltz DA; Singh PK; McKone EF; Welsh MJ
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.